Latest: FDA Approves New Biosimilar for Oncology Treatment
Pharmaceutical

Capvaxive shows strong immune response in children at risk of pneumococcal disease

by PharmaTimes
0 Comments
0 Mins
Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon Merck presents phase 3 STRIDE-13 trial results at ESCMID conference in Lisbon
Tags:
PharmaTimes
Author

PharmaTimes

Previous Post
Charlie Kirk Shooting: What To Know About Suspect and Event
Next Post
Recognising and managing protracted bacterial bronchitis in children
📢

Advertisement

300x250 Banner

Recent Content

COPD Biologics: Early Treatment Insights

Pulmonology • 2 hours ago

Antihypertensive Medication Guidelines

Cardiology • 4 hours ago

Juvenile Arthritis Care Transition

Rheumatology • 6 hours ago